Actinium Pharmaceuticals: Promising Developments and Strong Financial Position Drive Buy Rating

Tip Ranks
2025.12.13 17:55
portai
I'm PortAI, I can summarize articles.

Actinium Pharmaceuticals received a Buy rating from analyst Jason McCarthy of Maxim Group, with a $5.00 price target, due to promising developments in its ATNM-400 radiotherapy and strong financial position. The company has $53.4 million in cash, supporting future growth. H.C. Wainwright also reiterated a Buy rating with a $4.00 price target.

Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $5.00 price target.

Claim 50% Off TipRanks Premium and Invest with Confidence

  • Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
  • Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

Jason McCarthy has given his Buy rating due to a combination of factors related to Actinium Pharmaceuticals’ promising developments. Actinium’s ATNM-400, a targeted radiotherapy utilizing Actinium-225, has shown significant anti-tumor activity across various cancer types, including breast, lung, and prostate cancers. This includes effectiveness in treatment-resistant models, which positions Actinium as a leader in the radiopharmaceutical and antibody-drug conjugate sectors.
Furthermore, the company is well-capitalized with a strong financial position, having $53.4 million in cash at the end of the third quarter of 2025, providing a solid runway for continued development. The undisclosed target of ATNM-400, which is associated with tumor progression and resistance, adds a layer of intrigue and potential for future growth. These factors collectively underpin McCarthy’s optimistic outlook and Buy rating for Actinium Pharmaceuticals.

McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Plus Therapeutics, and SCYNEXIS. According to TipRanks, McCarthy has an average return of -7.8% and a 37.42% success rate on recommended stocks.

In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.